TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) has scheduled a conference call for Monday, August 4, 2025, at 8:30 AM ET to discuss their second quarter 2025 financial results and provide a business outlook. The call will be hosted by Michael S. Weiss, Chairman and Chief Executive Officer.
Investors can join via phone at 1-877-407-8029 (U.S.) or 1-201-689-8029 (international). A live webcast will be available on the company's website, and an audio recording will be accessible for 30 days afterward. Financial results will be released prior to the call.
TG Therapeutics (NASDAQ: TGTX) ha programmato una conference call per luned矛 4 agosto 2025 alle 8:30 AM ET per discutere i risultati finanziari del secondo trimestre 2025 e fornire una panoramica aziendale. La chiamata sar脿 condotta da Michael S. Weiss, Presidente e Amministratore Delegato.
Gli investitori potranno partecipare telefonicamente chiamando il 1-877-407-8029 (USA) o il 1-201-689-8029 (internazionale). Sar脿 disponibile una diretta streaming sul sito web dell'azienda e una registrazione audio rester脿 accessibile per 30 giorni. I risultati finanziari saranno pubblicati prima della chiamata.
TG Therapeutics (NASDAQ: TGTX) ha programado una llamada conferencia para el lunes 4 de agosto de 2025 a las 8:30 AM ET para discutir los resultados financieros del segundo trimestre de 2025 y ofrecer una perspectiva empresarial. La llamada ser谩 dirigida por Michael S. Weiss, Presidente y Director Ejecutivo.
Los inversores podr谩n unirse por tel茅fono llamando al 1-877-407-8029 (EE.UU.) o al 1-201-689-8029 (internacional). Habr谩 una transmisi贸n en vivo disponible en la p谩gina web de la empresa, y una grabaci贸n de audio estar谩 accesible durante 30 d铆as despu茅s. Los resultados financieros se publicar谩n antes de la llamada.
TG Therapeutics (NASDAQ: TGTX)电� 2025雲� 8鞗� 4鞚� 鞗旍殧鞚� 鞓れ爠 8鞁� 30攵�(霃欕秬 鞁滉皠)鞐� 2025雲� 2攵勱赴 鞛 鞁れ爜 氚� 靷梾 鞝勲鞚� 雲检潣頃橁赴 鞙勴暅 旎嵓霟办姢 旖滌潉 鞓堨爼頃橁碃 鞛堨姷雼堧嫟. 鞚措矆 旖滌潃 Michael S. Weiss 須岇灔 瓴� 斓滉碃瓴届榿鞛愱皜 欤检禍頃╇媹雼�.
韴瀽鞛愲摛鞚� 氙戈淡 雮挫棎靹湹鐢 1-877-407-8029, 甑牅 鞝勴檾电� 1-201-689-8029搿� 鞝勴檾頃橃棳 彀胳棳頃� 靾� 鞛堨姷雼堧嫟. 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞁れ嫓臧� 鞗轨簮鞀ろ姼臧� 鞝滉车霅橂┌, 鞓る敂鞓� 雲轨潓鞚� 鞚错泟 30鞚缄皠 鞚挫毄 臧�電ロ暕雼堧嫟. 鞛 鞁れ爜鞚� 旖� 鞝勳棎 瓿店皽霅╇媹雼�.
TG Therapeutics (NASDAQ: TGTX) a programm茅 une conf茅rence t茅l茅phonique pour le lundi 4 ao没t 2025 脿 8h30 ET afin de discuter des r茅sultats financiers du deuxi猫me trimestre 2025 et de pr茅senter les perspectives de l'entreprise. L'appel sera anim茅 par Michael S. Weiss, Pr茅sident et Directeur G茅n茅ral.
Les investisseurs peuvent participer par t茅l茅phone au 1-877-407-8029 (脡tats-Unis) ou au 1-201-689-8029 (international). Un webcast en direct sera disponible sur le site web de la soci茅t茅, et un enregistrement audio sera accessible pendant 30 jours apr猫s l'appel. Les r茅sultats financiers seront publi茅s avant la conf茅rence t茅l茅phonique.
TG Therapeutics (NASDAQ: TGTX) hat eine Telefonkonferenz f眉r Montag, den 4. August 2025, um 8:30 Uhr ET angesetzt, um die Finanzergebnisse des zweiten Quartals 2025 zu besprechen und einen Gesch盲ftsausblick zu geben. Die Konferenz wird von Michael S. Weiss, Vorsitzender und Chief Executive Officer, geleitet.
Investoren k枚nnen telefonisch unter 1-877-407-8029 (USA) oder 1-201-689-8029 (international) teilnehmen. Ein Live-Webcast wird auf der Webseite des Unternehmens verf眉gbar sein, und eine Audioaufzeichnung wird 30 Tage danach zug盲nglich sein. Die Finanzergebnisse werden vor der Telefonkonferenz ver枚ffentlicht.
- None.
- None.
Conference Call to be Held Monday, August 4, 2025, at 8:30 am ET
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook for the remainder of 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at . An audio recording of the conference call will also be available for replay at聽, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI庐 (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively.聽聽 For more information, visit and follow us on X (formerly Twitter) and on BRIUMVI庐 is a registered trademark of TG Therapeutics, Inc. BRIUMVI庐 is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email:
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email:
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics (TGTX) Q2 2025 earnings call?
How can I access TGTX's Q2 2025 earnings call?
Who will host TG Therapeutics' Q2 2025 earnings call?
Where can I find TGTX's Q2 2025 earnings call replay?
